Prime Medicine (Prime Medicine) Net Margin % : -7,742.98% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Prime Medicine's Net Income for the three months ended in Mar. 2024 was $-45.76 Mil. Prime Medicine's Revenue for the three months ended in Mar. 2024 was $0.59 Mil. Therefore, Prime Medicine's net margin for the quarter that ended in Mar. 2024 was -7,742.98%.

The historical rank and industry rank for Prime Medicine's Net Margin % or its related term are showing as below:

PRME' s Net Margin % Range Over the Past 10 Years
Min: -34601.86 Med: -65.45 Max: -65.45
Current: -34601.86

PRME's Net Margin % is ranked worse than
95.04% of 1028 companies
in the Biotechnology industry
Industry Median: -154.37 vs PRME: -34601.86

Prime Medicine Net Margin % Historical Data

The historical data trend for Prime Medicine's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Net Margin % Chart

Prime Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

-65.45

Prime Medicine Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial									-	-	-	-	-7,742.98

Competitive Comparison of Prime Medicine's Net Margin %

For the Biotechnology subindustry, Prime Medicine's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Net Margin % distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Net Margin % falls into.

Prime Medicine Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Prime Medicine's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-198.133	/	0
	=	%

Prime Medicine's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-45.761	/	0.591
	=	-7,742.98 %

Prime Medicine (NAS:PRME) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Prime Medicine Net Margin % Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prime Medicine (Prime Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Erie Street, Cambridge, MA, USA, 02139

Website

https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Executives

Gv 2019 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Thomas Cahill	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson	officer: See Remarks	88 SIDNEY STREET, CAMBRIDGE MA 02139
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Meredith Goldwasser	officer: SVP, Strategy & Corporate Ops.	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139